LLY Intrinsic Value Calculator – Eli Lilly Signs 750 Million Euro Partnership with Italy by 2025
October 26, 2023
🌥️Trending News
Eli ($NYSE:LLY) Lilly and Company, a global pharmaceutical leader, has recently signed a groundbreaking agreement with Italy valued at 750 million Euro by 2025. This major partnership marks a major milestone for the company, and is expected to lead to significant growth in the Italian market. As one of the world’s largest pharmaceutical companies, Eli Lilly has long been committed to providing innovative medicines that help improve patient lives and reduce healthcare costs worldwide. With this new agreement with Italy, Eli Lilly has once again demonstrated its commitment to driving healthcare innovation and providing access to life-saving medicines for patients everywhere. The agreement between Eli Lilly and Italy encompasses a range of strategic collaborations.
These include research and development initiatives, clinical studies, and public health programs for the Italian population. These initiatives are expected to create jobs and stimulate economic growth in the country while producing groundbreaking advances in patient care and medicine. As Eli Lilly continues to seek out new partnerships with other countries, the company is committed to driving positive change in healthcare through innovation and collaboration. With this latest agreement, it’s clear that Eli Lilly is firmly committed to its mission of improving patient outcomes around the world.
Stock Price
On Monday, ELI LILLY AND Co. (NYSE: LLY) stock opened at $586.1 and closed at $576.6, down by 1.4% from last closing price of 584.6. The deal between ELI LILLY AND and Italy includes investments in research and development, manufacturing, and distribution of the company’s medical products in the country. The partnership seeks to improve the accessibility and affordability of healthcare products in Italy, particularly in the areas of cardiovascular disease, oncology, diabetes, and Alzheimer’s disease. ELI LILLY AND is also looking to bring new jobs to the country by opening a new manufacturing facility in Italy.
The agreement between ELI LILLY AND and Italy is part of the company’s global strategy to expand its presence in Europe and other countries around the world. ELI LILLY AND is also looking to strengthen its presence in the Italian market, where it already has a strong customer base. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for LLY. More…
| Total Revenues | Net Income | Net Margin |
| 29.52k | 6.5k | 24.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for LLY. More…
| Operations | Investing | Financing |
| 5.74k | -2.55k | -3.03k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for LLY. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 54.81k | 43.66k | 11.65 |
Key Ratios Snapshot
Some of the financial key ratios for LLY are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.7% | 8.3% | 26.0% |
| FCF Margin | ROE | ROA |
| 10.9% | 43.1% | 8.7% |
Analysis – LLY Intrinsic Value Calculator
At GoodWhale, we recently completed an analysis of the fundamentals of ELI LILLY AND. Our proprietary Valuation Line has determined that the fair value of the ELI LILLY AND share is around $310.9. Currently, the stock is being traded at $576.6, indicating that it is overvalued by 85.5%. This means that investors should exercise caution if they are considering investing in this company right now. More…
Peers
The competition between Eli Lilly and Co and its competitors is intense. Biogen Inc, Pfizer Inc, and Merck & Co Inc are all major players in the pharmaceutical industry, and each company is striving to be the top dog. Eli Lilly and Co has a strong presence in the United States, but its competitors are not far behind.
– Biogen Inc ($NASDAQ:BIIB)
Biogen Inc is an American multinational biotechnology company. The company is headquartered in Cambridge, Massachusetts, and has offices in Weston, Massachusetts; Research Triangle Park, North Carolina; Zurich, Switzerland; Maidenhead, United Kingdom; and Tokyo, Japan. Biogen Inc researches, develops, and manufactures therapies for the treatment of neurological and neurodegenerative diseases. The company’s products include AVONEX, TYSABRI, and FAMPYRA.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc has a market cap of 244.98B as of 2022, a Return on Equity of 24.63%. The company focuses on the discovery, development, and manufacture of biopharmaceutical products. Its portfolio includes medicines and vaccines for a wide range of conditions and diseases, such as Alzheimer’s disease, arthritis, cancer, and diabetes.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. The company was established in 1891 as the United States subsidiary of the German company Merck, which was founded in 1668 by the Merck family. Merck & Co. was subsequently acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. The company is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.
Merck’s market cap is 238.43B as of 2022. The company has a Return on Equity of 28.84%. Merck & Co. is a multinational pharmaceutical company that is one of the largest in the world. The company was established in 1891 and has been acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. Merck & Co. is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.
Summary
Eli Lilly has recently announced a new pact with Italy, worth 750 million dollars by 2025. This investment will strengthen the firm’s foothold in the Italian market and enable it to expand its operations in the country. Analysts have noted that this move by Eli Lilly signals a long-term commitment to the Italian market and will likely result in a higher market share for the company.
The agreement is seen as a positive move, as it will help the company increase its revenues and establish itself as a major pharmaceutical player in the region. This investment is expected to bring in additional profits for Eli Lilly, as well as help the company diversify its portfolio of products and services.
